Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gifford Lorenz

Pulmonary Disease Savannah, GA Medical Doctor

NPI 1912076944 CMS profile 222848

5354 Reynolds St, Suite 318, Savannah, GA 31405

Open in the dashboard

General payments

$20,293

353 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gifford Lorenz of Savannah, GA is reported in the CMS Open Payments database as having received $20,293 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21 1
2024 General $23 1
2023 General $786 30
2022 General $2,471 110
2021 General $1,555 74
2020 General $3,023 40
2019 General $12,415 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gifford Lorenz
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Gifford Lorenz were reported at $21. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Gifford Lorenz Pulmonary Disease median Middle half National median
2019 $12,415 $377 $109–$1,340 $163
2020 $3,023 $230 $56–$907 $114
2021 $1,555 $269 $68–$1,072 $132
2022 $2,471 $390 $100–$1,457 $149
2023 $786 $419 $114–$1,659 $160
2024 $23 $476 $123–$1,818 $164
2025 $21 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Insmed, Inc. $13,424 29 payments
  2. GlaxoSmithKline, LLC. $1,467 75 payments
  3. AstraZeneca Pharmaceuticals LP $1,191 53 payments
  4. Grifols USA, LLC $981 46 payments
  5. Mallinckrodt Hospital Products Inc. $372 9 payments
  6. Merck Sharp & Dohme Corporation $275 13 payments
  7. Regeneron Healthcare Solutions, Inc. $273 12 payments
  8. Electromed, Inc. $252 22 payments
  9. Actelion Pharmaceuticals US, Inc. $235 8 payments
  10. Jazz Pharmaceuticals Inc. $230 11 payments
  11. Other $1,591 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,550 2 payments
  2. Food and Beverage $7,373 340 payments
  3. Consulting Fee $2,700 3 payments
  4. Travel and Lodging $1,378 3 payments
  5. Education $292 5 payments
Products named General payments · program years 2019–2025
  1. Arikayce $11,705 26 payments
  2. Prolastin-C Liquid $844 44 payments
  3. TRELEGY ELLIPTA $708 43 payments
  4. NUCALA $426 19 payments
  5. ACTHAR $372 9 payments
  6. BREZTRI $334 13 payments
  7. DUPIXENT $273 12 payments
  8. TEZSPIRE $194 6 payments
  9. FASENRA $176 10 payments
  10. SMARTVEST $157 16 payments
  11. Other $3,098 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record